Anthos Therapeutics Announces that Abelacimab has Received FDA Fast Track Designation for the Treatment of Thrombosis Associated with Cancer

Abelacimab is a dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa with high affinity and selectivity Earlier this year abelacimab became the first-ever Factor XI inhibitor to begin enrolling patients in a Phase 3 trial ... Biopharmaceuticals, FDA Anthos Therapeutics, abelacimab, Factor XI inhibitor, thrombosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news